eBulletin Newsletter
NCCN Flash Updates: NCCN Guidelines Updated for Mesothelioma: Pleural and Peritoneal
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Mesothelioma: Pleural. These NCCN Guidelines® are currently available as Version 2.2024.
Link directly to the Updates section of the NCCN Guidelines: Mesothelioma: Pleural
PM-B 1 of 3
- First-line therapy
- Epithelioid, Biphasic or Sarcomatoid
- The following regimen added as a preferred treatment option
- (Cisplatin or carboplatin) + pemetrexed + pembrolizumab (category 1)
- Carboplatin added as an alternate option to cisplatin in combination with pemetrexed ± bevacizumab. Previously noted for patients who are not candidates for cisplatin (footnote d).
- The following regimen added as a preferred treatment option
- Epithelioid, Biphasic or Sarcomatoid
- Footnote removed: The combination regimens of pemetrexed/cisplatin/bevacizumab, pemetrexed/carboplatin/bevacizumab, and nivolumab/ipilimumab are only for unresectable disease
PM-B 2 of 3
- References added
- 7 Popat S, Felip E, Dafni U, et al. BEAT-meso: A randomized phase III study of bevacizumab and standard chemotherapy with or without atezolizumab, as first-line treatment for advanced pleural mesothelioma—Results from the ETOP 13-18 trial. J Clin Oncol 2024; 42(suppl 17; abstr LBA8002).
- 8 Chu Q, Perrone F, Greillier L, et al. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. Lancet 2023;16;402:2295-2306.
PM-B 3 of 3
- Reference removed:
- Popat S, Curioni-Fontecedro A, Dafni U, et al. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Ann Oncol 2020;31:1734-1745.
NCCN has published updates to the NCCN Guidelines and NCCN Compendium® for Mesothelioma: Peritoneal. These NCCN Guidelines are currently available as Version 3.2024.
Link directly to the Updates section of the NCCN Guidelines: Mesothelioma: Peritoneal
PEM-C 1 of 3
- First-line therapy
- Epithelioid, Biphasic or Sarcomatoid
- The following regimen added as a preferred treatment option
- (Cisplatin or carboplatin) + pemetrexed + pembrolizumab
- Carboplatin added as an alternate option to cisplatin in combination with pemetrexed ± bevacizumab. Previously noted for patients who are not candidates for cisplatin (footnote d).
- The following regimen added as a preferred treatment option
- Epithelioid, Biphasic or Sarcomatoid
PEM-C 2 of 3
- References added
- 9 Popat S, Felip E, Dafni U, et al. BEAT-meso: A randomized phase III study of bevacizumab and standard chemotherapy with or without atezolizumab, as first-line treatment for advanced pleural mesothelioma—Results from the ETOP 13-18 trial. J Clin Oncol 2024; 42(suppl 17; abstr LBA8002).
- 10 Chu Q, Perrone F, Greillier L, et al. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. Lancet 2023;16;402:2295-2306.
For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium®), the NCCN Biomarkers Compendium®, the NCCN Chemotherapy Order Templates (NCCN Templates®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.
To view the NCCN Guidelines for Patients®, please visit NCCN.org/patientguidelines.
Free NCCN Guidelines apps for iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps.
About NCCN Flash Updates™
NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium®, and other NCCN Content.
Subscribe to NCCN Flash Updates™
Third Party Content: The NCCN Content may contain content (such as figures, tables or illustrations) that NCCN licenses from third parties as displayed on NCCN Third Party Content site: private.filesanywhere.com/fs/v.aspx?v=8a6d65cfa19ea4bda0a3&C=6241. Licensee shall be solely responsible for obtaining permissions from each such third party to use any such Third Party Content in the Permitted Works.
Access information on permissions and licensing of NCCN Content
Users may unsubscribe from Flash Updates at any time by contacting us. NOTE: The subscription fee for NCCN Flash Updates™ is non-refundable.